Department of Endocrine Oncology, University Medical Center Utrecht, Utrecht, Netherlands.
Dutch MEN Advocacy Group, Department of Endocrine Oncology, University Medical Center Utrecht, Utrecht, Netherlands.
J Clin Endocrinol Metab. 2018 Jun 1;103(6):2354-2361. doi: 10.1210/jc.2018-00259.
Multiple endocrine neoplasia type 1 (MEN1) is a hereditary disease characterized by a high risk of developing primary hyperparathyroidism, duodenopancreatic neuroendocrine tumors, and pituitary tumors (PITs). It is unclear if having MEN1 leads to psychological distress because of fear of disease occurrence (FDO), thereby potentially affecting quality of life.
A cross-sectional study was performed using the Dutch MEN1 cohort. All patients received the Cancer Worry Scale (a score ≥14 reflects high FDO), the Medical Outcomes Study 36-item Short-Form Health Survey (SF-36), and questions on sociodemographic and medical history.
A total of 227 of 285 (80%) eligible patients with MEN1 completed the questionnaire. The mean (± standard deviation) age was 47 ± 15 years. Overall, patients experienced an FDO of 15.1 ± 4.7, with 58% of patients having a score ≥14. This is higher than reported in previous studies assessing fear of cancer recurrence in different cancer populations (31% to 52%). Adjusted for age and sex, the FDO score was negatively associated with almost all SF-36 subscales. In multivariable analysis, the diagnosis of a PIT, a pancreatic neuroendocrine tumor, and not being employed were associated with FDO (P < 0.05). Patients had higher FDO scores for their family members than for themselves.
The majority of patients with MEN1 have FDO for themselves and even more for their relatives. This psychological distress is associated with a lower health-related quality of life. Therefore, in the medical care for MEN1, emphasis should also be placed on FDO and quality of life.
多发性内分泌腺瘤病 1 型(MEN1)是一种遗传性疾病,其特征是发生原发性甲状旁腺功能亢进、十二指肠胰腺神经内分泌肿瘤和垂体瘤(PIT)的风险较高。目前尚不清楚患有 MEN1 是否会因担心疾病发生(FDO)而导致心理困扰,从而潜在地影响生活质量。
采用荷兰 MEN1 队列进行横断面研究。所有患者均接受癌症担忧量表(得分≥14 反映高度 FDO)、医疗结局研究 36 项简明健康调查量表(SF-36)以及社会人口统计学和病史问题的调查。
285 名符合条件的 MEN1 患者中,共有 227 名(80%)完成了问卷调查。患者的平均(±标准差)年龄为 47±15 岁。总体而言,患者的 FDO 为 15.1±4.7,58%的患者得分≥14。这高于先前评估不同癌症人群中对癌症复发恐惧的研究报告(31%至 52%)。校正年龄和性别后,FDO 评分与 SF-36 几乎所有子量表均呈负相关。多变量分析显示,PIT、胰腺神经内分泌肿瘤的诊断以及未就业与 FDO 相关(P<0.05)。患者对家庭成员的 FDO 评分高于对自己的 FDO 评分。
大多数 MEN1 患者对自己存在 FDO,对亲属的 FDO 甚至更多。这种心理困扰与健康相关生活质量降低有关。因此,在 MEN1 的医疗护理中,也应重视 FDO 和生活质量。